Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04765592
Other study ID # WEIQIANG202001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 7, 2021
Est. completion date February 5, 2029

Study information

Verified date April 2024
Source Hangzhou Endonom Medtech Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for true/false aortic arch aneurysms and ulcers involving aortic arch . (GIANT Study)


Description:

This study is a prospective ,multiple center study about the safety and efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System, it is expected to complete the implantation of 80 patients in 23 centers within 12 months, and interim follow-up was conducted before discharge, 30 days after surgery, 6 months after surgery and 12 months after surgery, long-term follow-up will be performed at 24 months postoperatively, 36 months postoperatively, 48 months postoperatively and 60 months postoperatively.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 88
Est. completion date February 5, 2029
Est. primary completion date February 5, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patients aged 18 to 80 years old; 2. Diagnosed with aortic arch lesions requiring intervention, including true aortic arch aneurysms, pseudo-aortic arch aneurysms, and ulcers involving the aortic arch; 3. Showing a suitable vascular condition, including: - Ascending aorta length greater than 50 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery). - Ascending aorta diameter = 24 mm and = 48 mm; - Proximal anchoring zone length = 30 mm; - Innominate artery diameter = 24 mm and = 7 mm, length = 20 mm; - Left common carotid artery or left subclavian artery diameter = 24 mm and = 7 mm, length = 20 mm; - Suitable arterial access for endovascular interventional treatment; 4. Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol. 5. Evaluated by at least two vascular surgeons or cardiac surgeons as high surgical risk patients or deemed to have significant surgical contraindications. Exclusion Criteria: 1. Experienced systemic infection during past three months; 2. Neck surgery was performed within 3 months; 3. Previous endovascular interventional treatment involving the aortic arch was performed; 4. Infectious aortic disease?Takayasu arteritis,Marfan syndrome (or other connective tissue diseases ); 5. Severe stenosis, calcification, thrombosis, or tortuosity of the carotid or subclavian artery; 6. Heart transplant; 7. Suffered MI or stroke during past three months; 8. Class IV heart function (NYHA classification); 9. Active peptic ulcers or upper gastrointestinal bleeding occurring within the previous three months; 10. Hematological abnormality, defined as follows: Leukopenia (WBC < 3 × 109/L), acute anemia (Hb < 90 g/L); thrombocytopenia (PLT count < 50 × 109/L), history of bleeding or coagulopathy; 11. Renal insufficiency, creatinine > 265 umol/L (or 3.0mg/dL) and/or end-stage renal disease requiring renal dialysis, as determined by an investigator after a thorough analysis; 12. Pregnant or breastfeeding; 13. Allergies to contrast agents; 14. Life expectancy of less than 12 months; 15. Participating in another drug or device research; 16. Any other disease or abnormality that the investigators believe may hinder endovascular interventional treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
WeFlow-Arch Modeler Embedded Branch Stent Graft System
The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.

Locations

Country Name City State
China Beijing Anzhen Hospital, Capital Medical University Beijing
China Chinese PLA General Hospital Beijing
China Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing
China Peking University People's Hospital Beijing
China Xiangya Hospital of Central South University Changsha
China West China Hospital of Sichuan University Chengdu
China The First Affiliated Hospital ,Sun Yat-sen University Guangzhou
China First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou
China Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou
China The Second Affiliated Hospital of Harbin Medical University Harbin
China Shandong Provincial Hospital Jinan
China The First People's Hospital of Yunnan Province Kunming
China Nanjing Drum Tower Hospital Nanjing
China Nanjing First Hospital Nanjing
China The Affiliated Hospital Of Qingdao University Qingdao
China Renji Hospital, Shanghai Jiaotong University School of Medicine Shanghai
China The Ninth People's Hospital, Shanghai Jiaotong University School of Medicine Shanghai
China Zhongshan Hospital, Fudan University Shanghai
China The First Affiliated Hospital of China Medical University Shenyang
China The First Affiliated Hospital Of Soochow University Suzhou
China Tianjin Medical University General Hospital Tianjin
China The First Affiliated Hospital of PLA Air Force Military Medical University Xian
China First Affiliated Hospital of Zhengzhou University Zhengzhou

Sponsors (1)

Lead Sponsor Collaborator
Hangzhou Endonom Medtech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of all-cause mortality and major stroke within 12 months after surgery All-cause mortality includes cardiac mortality, non-cardiac mortality, and mortality from unknown causes. Severe stroke is defined as a modified Rankin score (mRS) = 2 at 90 days following stroke onset. 12 months after surgery
Secondary Rate of immediate technical success following surgery Immediate technical success is defined as successful delivery of the aortic and branching stent graft conveyors to their predetermined positions, accurate positioning and successful deployment of the stent, safe removal of the delivery device outside the body, and the absence of Type I and III endoleaks per imaging studies conducted at the end of the procedure with all branching stents patency. immediately after the surgery
Secondary Rate of aortic aneurysm progression under control Aortic aneurysm progression under control is defined as maximum increase in the diameter of the aortic aneurysm was = 5 mm when compared with preoperative aortic aneurysm as of a 12-month postoperative CTA review 12 months after operation
Secondary Incidence of Type I or Type III endoleak Incidence of Type I or Type III endoleak before discharge, 1 month, 6 months, 12 months after operation. Intraoperative endoleaks subject to adjuvant treatment are not recorded. Endoleaks occurring after the completion of the procedure followed by one or more endoleaks occurring in the same subject at different follow-up stages that were not treated are counted as a single instance. immediately after the surgery, 1 month, 6 months, 12 months after the surgery
Secondary Incidence of aortic arch stent graft displacement CTA examination will be performed at 1 month, 6 months, and 12 months post operation to determine if the stent has migrated, and evaluations will be recorded for both the main and branch stents. Displacement is defined as a nodal aortic or branching stent graft displacement of more than 10 mm from pre-discharge levels. 1 month, 6 months, 12 months after operation
Secondary Postoperative branch vessel patency rate CTA examinations will be performed at 1 month, 6 months, and 12 months post operation to evaluate branch vessel reconstruction and assess for occlusion, stenosis, or in-stent thrombosis. 1 month, 6 months, 12 months after operation
Secondary Incidence of surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention Incidence of surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention 30 days, 6 months, and 12 months after operation.Whether or not the patient experienced surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention will be determined. 30 days, 6 months, and 12 months after operation
Secondary Rate of major adverse events Refers to all-cause mortality, myocardial infarction, ischemic stroke, or respiratory failure occurring within 30 days after surgery. More specifically, myocardial infarction refers to a drastic reduction or complete interruption of the coronary blood supply due to coronary artery disease, resulting in severe and prolonged acute ischemia of the corresponding myocardium, leading to necrosis of cardiomyocytes. Ischemic stroke refers to the result of necrosis of brain tissue caused by narrowing or occlusion of the arteries supplying blood to the brain or insufficient blood supply to the brain. Respiratory failure is defined as a state resulting in significantly prolonged intubation, tracheotomy, deterioration of lung function, or other fatal outcomes. 30 days post operation
Secondary Rate of aortic aneurysm-related mortality Refers to mortality caused by a ruptured aortic aneurysm or endovascular interventional treatment. 12 months post operation
Secondary Incidence of severe adverse events Refers to an event that occurs during the clinical trial that results in mortality or serious deterioration in patient health, including a fatal illness or injury, a permanent defect in body structure or body function, or an event that requires medical or surgical intervention to avoid one or more permanent defects in body structure or body function. 30 days, 6 months, and 12 months after operation
Secondary Incidence of device-related adverse events Device-related adverse events refer to an adverse medical event related to the use of a device that occurs during the clinical trial. However, a distinction should be made with respect to normal postoperative stress response, such as fever and chest and back discomfort, which, in the judgment of the investigator, need not be recorded as an adverse event. Recording of device-related adverse events will be applicable for conditions that are deemed by the investigator to be definitely related, possibly related, or of indeterminate relationship, to the test device. 30 days, 6 months, and 12 months after operation
See also
  Status Clinical Trial Phase
Completed NCT04489277 - Silent Brain Infarction After Endovascular Arch Procedures
Recruiting NCT03347812 - Clinical Study for Evaluating the Safety and Efficacy of Total Endovascular Aortic Arch Repair N/A
Recruiting NCT05896397 - European Aortic Data Collection Project
Active, not recruiting NCT05421130 - Clinical Investigation of Clinical Safety and Performance of the SP-GRIPFLOW, Selective Cerebral Perfusion Catheter When Used for Cerebral Perfusion During Aortic Arch Repair N/A
Recruiting NCT02050113 - Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices N/A
Recruiting NCT02089607 - Complex Abdominal, TAAA, Aortic Arch Aneurysm or Dissections With Fenestrated/Branched Stent Graft N/A
Recruiting NCT06385379 - Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study) N/A
Completed NCT04909190 - Saline Flush to Reduce the Amount of Residual Air Inside a Stentgraft Delivery System N/A
Enrolling by invitation NCT01654133 - Evaluation of Visceral Function Following Endovascular Aortic Aneurysm Repair Using Branched Stent- Grafts N/A
Completed NCT04833283 - The Effects of Intermittent Hypoxic-hyperoxic Preconditioning for Patients Undergoing Cardiopulmonary Bypass. N/A
Recruiting NCT01524211 - Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms N/A
Completed NCT04809896 - Homemade Fenestrated Physician-modified Stent-grafts for Arch Aortic Degenerative Aneurysm
Completed NCT04244188 - Simulation of Stent-graft Deployment in Aortic Arch Aneurysms
Recruiting NCT05530304 - Outcome of a Triple Inner Branched Aortic Arch Stentgraft. A Prospective, Multicenter Registry.
Completed NCT03420066 - The NEXUS™ Compassionate Use Data Collection Study